RNA Interference and Its Potential Applications to Chronic HBV Treatment: Results of a Phase I Safety and Tolerability Study

Abstract

Background

RNA interference (RNAi) provides an attractive tool to modulate biological systems, and ultimately, to treat human diseases. We describe early results from a Phase Ib, first-in-human safety and tolerability study of an RNAi-based therapy, NUC B1000, among patients with mild to moderate chronic HBV.

Methods

Three subjects received a single 5 mg DNA dose of NUC B1000 as part of a planned dose escalation study.

Results

All participants reported pharyngitis, chills, myalgia and fever approximately 4–7 h after dosing. All subjects were asymptomatic after a single antipyretic dose with no symptom recurrences. Measurements of interferon (IFN)-α and -γ, interleukin (IL)-10, 12 18, 8 and 6, and tumour necrosis factor-α performed before and after dosing revealed cytokine increases before study drug administration. After drug administration, IFN-γ and IL-10 increased in two patients; IL-8 increased in one. Most increases returned to pretreatment levels within 1 week. Two patients were subsequently successfully treated with entecavir indicating that NUC B1000 does not compromise subsequent antiviral therapy.

Conclusions

Thus far, NUC B1000 appears safe and well-tolerated; safety and efficacy studies across a larger, more diverse patient spectrum using increasing doses are needed to determine its appropriate role in the antiviral armamentarium.

References

Hajeri

P.B.

, Singh

S.K.

siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs. Drug Discov Today 2009; 14: 851–858.

Singh

S.K.

, Hajeri

P.B.

siRNAs: their potential as therapeutic agents – Part II. Methods of delivery. Drug Discov Today 2009; 14: 859–865.

Stevenson

Therapeutic potential of RNA interference. N Engl J Med 2004; 351: 1772–1777.

Lee

R.C.

, Feinbaum

R.L.

, Ambros

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–854.

Fire

, Xu

, Montgomery

M.K.

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.

Grimm

, Streetz

K.L.

, Jopling

C.L.

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537–541.

Guo

, Kemphues

K.J.

Molecular genetics of asymmetric cleavage in the early Caenorhabditis elegans embryo. Curr Opin Genet Dev 1996; 6: 408–415.

Napoli

, Lemieux

, Jorgensen

Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2: 279–289.

Recombinant DNA Advisory Committee (RAC). 2006 Past RAC meetings. Office of Biotechnology Activities. 2006. National Institutes of Health. (Updated 27 October 2010. Accessed 28 August 2009.) Available from http://oba.od.nih.gov/rdna/rac_past_meeting_2006_webcasts.html#dec06, http://oba.od.nih.gov/rdna_rac/rac_past_meetings_2000.html#RAC2006.

10.

Winston

W.M.

, Molodowitch

, Hunter

C.P.

Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science 2002; 295: 2456–2459.

11.

Wolfrum

, Shi

, Jayaprakash

K.N.

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25: 1149–1157.

12.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

13.

US Food and Drug Administration, Department of Health and Human Services. Adverse event reporting system (AERS). (Updated 20 August 2009. Accessed 25 October 2010.) Available from http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.

14.

Sioud

Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348: 1079–1090.

15.

Chang

J.J.

, Thompson

A.J.

, Visvanathan

The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 2007; 46: 1332–1340.

16.

Kanzler

, Barrat

F.J.

, Hessel

E.M.

, Coffman

R.L.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552–559.

17.

Robbins

M.A.

, Li

, Leung

Stable expression of shRNAs in human CD34⁺ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006; 24: 566–571.